TY - JOUR
T1 - Potential therapeutic strategies of regenerative medicine for renal failure
AU - Mata-Miranda, Monica Maribel
AU - Delgado-Macuil, Raul Jacobo
AU - Rojas-Lopez, Marlon
AU - Martinez-Flores, Ricardo
AU - Vazquez-Zapien, Gustavo Jesus
N1 - Publisher Copyright:
© 2017 Bentham Science Publishers.
PY - 2017
Y1 - 2017
N2 - Background: Kidney diseases are a public health problem worldwide. Available therapies include function replacement by dialysis or transplant, which are associated with a high morbidity and mortality. Likewise, none of these treatments compensate all kidney functions. There is a great concern in developing more effective therapies with the ability to replace the wide range of renal functions, so that, new studies on developing therapeutic strategies have focused on regenerative medicine. Objective: The aim of this paper is to review the new advances in regenerative medicine for renal failure treatment. Results: Regenerative medicine comprises two therapeutic strategies: cell therapy and tissue engineering. Cell therapy techniques depend on cell and tissue cultures, with the aim to replace morphological structures, tissues, and functions. The main strategic strength of cell therapy in renal failure is the incorporation of additional cells in a damaged kidney, for which purpose different kind of Stem Cells (SCs) have been used such as Embryonic SCs, induced Pluripotent SCs, Multipotent SCs, Renal SCs, or drugs that increase survival and mobilization of SCs. Tissue engineering complements cell therapy combining techniques of biological sciences and engineering to create structures and devices as scaffolds, matrices or 3D biocompatible materials. Conclusion: Even though there is a significant advance in regenerative medicine strategies, we are far from using any of its techniques on health institutions, due to it is necessary to evaluate side effects, biodistribution, dosage, type of administration, vehicle of cell therapy, as well as the evaluation of response time and long-term studies, among other studies.
AB - Background: Kidney diseases are a public health problem worldwide. Available therapies include function replacement by dialysis or transplant, which are associated with a high morbidity and mortality. Likewise, none of these treatments compensate all kidney functions. There is a great concern in developing more effective therapies with the ability to replace the wide range of renal functions, so that, new studies on developing therapeutic strategies have focused on regenerative medicine. Objective: The aim of this paper is to review the new advances in regenerative medicine for renal failure treatment. Results: Regenerative medicine comprises two therapeutic strategies: cell therapy and tissue engineering. Cell therapy techniques depend on cell and tissue cultures, with the aim to replace morphological structures, tissues, and functions. The main strategic strength of cell therapy in renal failure is the incorporation of additional cells in a damaged kidney, for which purpose different kind of Stem Cells (SCs) have been used such as Embryonic SCs, induced Pluripotent SCs, Multipotent SCs, Renal SCs, or drugs that increase survival and mobilization of SCs. Tissue engineering complements cell therapy combining techniques of biological sciences and engineering to create structures and devices as scaffolds, matrices or 3D biocompatible materials. Conclusion: Even though there is a significant advance in regenerative medicine strategies, we are far from using any of its techniques on health institutions, due to it is necessary to evaluate side effects, biodistribution, dosage, type of administration, vehicle of cell therapy, as well as the evaluation of response time and long-term studies, among other studies.
KW - Cell therapy
KW - Potential therapeutic strategies
KW - Regenerative medicine
KW - Renal failure
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=85025130192&partnerID=8YFLogxK
U2 - 10.2174/1574888X12666170317163416
DO - 10.2174/1574888X12666170317163416
M3 - Artículo de revisión
C2 - 28322169
SN - 1574-888X
VL - 12
SP - 423
EP - 431
JO - Current Stem Cell Research and Therapy
JF - Current Stem Cell Research and Therapy
IS - 5
ER -